Pediculicide Drug Class List

Drugs in Drug Class: Pediculicide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Lifesciences	IVERMECTIN	ivermectin	CREAM;TOPICAL	215210-001	Aug 2, 2022	AB	RX	No	No
Taro	IVERMECTIN	ivermectin	LOTION;TOPICAL	210720-001	May 6, 2020		OTC	No	No
Zydus Lifesciences	IVERMECTIN	ivermectin	TABLET;ORAL	216863-001	Feb 26, 2026	AB	RX	No	No
Teva Pharms Usa	IVERMECTIN	ivermectin	CREAM;TOPICAL	210019-001	Sep 13, 2019	AB	RX	No	No
Rubicon Research	IVERMECTIN	ivermectin	TABLET;ORAL	215922-001	Jan 22, 2025	AB	RX	No	No
Rubicon Research	IVERMECTIN	ivermectin	TABLET;ORAL	215922-002	Jan 22, 2025		RX	No	No
Senores Pharms	IVERMECTIN	ivermectin	TABLET;ORAL	218324-001	Oct 16, 2024	AB	RX	No	No

Pediculicide Market Dynamics and Patent Landscape: What Drives Pricing, Generic Entry Risk, and IP Exclusivity by Product Type

Last updated: June 24, 2026

The pediculicide market is fragmented across actives and dosage forms (topical lotions, creams, shampoos, and device-assisted regimens). Patent and regulatory exclusivity are typically concentrated in specific originator formulations and, less often, in method-of-use or manufacturing improvements. As a result, market dynamics track (1) active-ingredient cycles (permethrin, pyrethrins/piperonyl butoxide, ivermectin, spinosad), (2) resistance-driven label expansion or reformulation, and (3) FDA approval pathway timing that determines when generics and “AB-rated” substitutes can enter. Patent estates tend to be narrow and product-specific, which raises generic entry risk once Orange Book-listed patents expire or are successfully challenged.

What patents protect pediculicides (permethrin, ivermectin, spinosad) and which companies own them?

Pediculicides do not have a single, unified patent estate. Protection is split by active ingredient and by product presentation (cream/lotion/shampoo, vehicle, concentration, and sometimes device-based regimens). In practice, patent protection clusters around three areas: formulation (vehicle and concentration), method-of-use (treatment regimens and repeat dosing windows), and manufacturing (process and stability).

Permethrin pediculicide patent ownership: what typically gets protected?

Most permethrin products in the US are older. Patent protection for permethrin pediculicide is largely expected to be historical, with later protection (where present) usually tied to:

• formulation changes (carrier/vehicle, viscosity, skin penetration aids)
• concentration or dosing regimen refinements
• combination claims (for example, pairing permethrin with other actives, although not common across US OTC and Rx lines)

Ivermectin (topical/oral) pediculicide patents: what typically gets protected?

Ivermectin is the key modern prescription/investigational pediculicide active. Patent estates commonly focus on:

• specific pharmaceutical compositions (topical ivermectin formulations)
• concentration ranges and excipient systems
• dosing regimens and patient-selection method-of-use claims

Spinosad pediculicide patents: how protection usually maps to the product?

Spinosad is frequently protected by product-specific claims because the formulation and dosage regimen matter to clinical performance and stability. Patent coverage typically concentrates in:

• composition claims (active stability in a particular vehicle)
• method-of-use claims around treatment and retreatment schedules

Key structural point for investors and litigators

When a pediculicide’s Orange Book listings are thin or limited to one or two formulation patents, the primary litigation risk for generics shifts from “freedom to operate” in the abstract to the ability to clear specific listed claims. For market entrants, the commercial risk is timing-based: the product may be patent-expired or legally vulnerable long before the last regulatory exclusivity ends.

---

What is the Orange Book status of pediculicides and how do listed patents drive exclusivity?

How to read the Orange Book for pediculicides

For any given NDC and dosage form, Orange Book status is usually decisive in these ways:

1. Listed drug product patents: composition and formulation claims tied to the approved product.
2. Listed method-of-use patents: claims tied to treatment protocols.
3. Patent expiry gates: the first patent expiration can allow generic entry if no additional listed patents remain “active” for that NDA.

In pediculicides, “active” listing patterns are often narrow. That typically results in:

• shorter windows of sustained patent blocking for generic firms
• more frequent “staggered” entry depending on the specific patent listed for that NDC

Featured snippet answer

Orange Book status in pediculicides usually hinges on one to a few product-specific formulation patents rather than broad, multi-patent coverage across the entire class.

---

When do major pediculicide patents expire and when does generic entry become possible?

Exclusivity timelines in pediculicides: the practical gating factors

Even where patents expire, generic entry timing can also be constrained by:

• remaining listed patents on the same NDA/NDC
• regulatory exclusivity (when applicable)
• litigation stays triggered by Paragraph IV filings

Typical pediculicide timeline logic used in market forecasting

• Identify the NDA and NDC.
• Map listed patents to their statutory expiration dates.
• Overlay any pediatric exclusivity extensions.
• Track Paragraph IV filings and potential 30-month stays.

In most pediculicide segments, the “patent estate to launch” lead time is short enough that generics can enter shortly after the last relevant listed patent expires, absent active litigation.

---

Which formulations are protected by pediculicide patents (lotions, creams, shampoos) and what vehicles create IP barriers?

Formulation IP barriers commonly seen across pediculicides

Patent barriers are most likely in claims that cover:

• specific concentration and viscosity ranges
• excipient systems that affect spreading and adherence
• stability claims related to degradation over shelf life

Dosage form matters

Even within the same active ingredient, patent coverage often depends on the dosage form:

• lotions and creams can be separately claimed
• shampoos can have different excipient and stability systems
• device-assisted or regimen-based products can shift claims toward combination use

Commercial implication

Generic entrants may achieve AB-rating on active ingredient but still face infringement risk if their vehicle falls within claim ranges.

---

How strong is the patent estate for pediculicides and how do courts typically treat method-of-use vs formulation claims?

Patent strength assessment by claim type

• Formulation patents: usually stronger for product-specific differentiation because infringement can be determined by composition and stability testing. They also tend to be narrower and easier to design around if the generic can step outside concentration or excipient ranges.
• Method-of-use patents: often litigated on inducement and on whether physicians and pharmacists follow the claimed protocol. In pediculicides, labeling and instructions matter heavily because physicians tend to follow label guidance.

What this means for litigation posture

If a pediculicide’s key patents are method-of-use, the infringement case often depends on proof that:

• the claimed regimen is being prescribed or used as specified
• the labeling instructs performance of the method
• inducement elements are met

For formulation-heavy estates, the case tends to turn on comparative composition and manufacturing reproducibility.

---

What patent litigation affects pediculicides and how do Paragraph IV challenges play out?

Typical litigation patterns in pediculicides

Pediculide disputes tend to resolve in predictable ways:

• Narrow claim construction around excipients, concentration ranges, or stability endpoints
• Settlements that allow “at-risk” launch either immediately upon expiry or after a short delay
• Design-around strategies that change vehicle or dosing regimen while maintaining bioequivalence or AB-rating

Paragraph IV as a market lever

Because pediculicide patent estates often have limited breadth, Paragraph IV filings can function as a timing strategy rather than a permanent market shield for challengers. Settlements can set a hard launch date for generics that originators may not be able to block further.

---

Do pediculicides face biosimilar-type risk, or is the market purely small-molecule/generic?

Pediculicides are generally small-molecule topical products; biosimilar frameworks are not usually relevant. Competitive risk is therefore dominated by:

• small-molecule generics and authorized generics
• OTC competitive substitution and switch behavior
• device/regimen adoption in prescription segments

---

How does pediculicide market competition differ between OTC and prescription channels?

OTC pediculicides

• Pricing tends to be driven by brand strength, retailer placement, and resistance perceptions.
• Patent value is often lower because many OTC actives have older patent histories and broad generic availability.

Prescription pediculicides

• Fewer products and tighter labeling create clearer product differentiation.
• Patent and exclusivity leverage is usually stronger because the originator’s product often has higher regulatory and marketing spend and more targeted clinical claims.

Commercial implication

Prescription products typically preserve market share longer because prescribers and payer formularies respond slower than OTC consumers, even when generics exist.

---

How do patent estates affect pricing and revenue exposure for pediculicide originators?

Revenue exposure concentrates around protectable “product advantages”

Originators protect market share through:

• labeled regimen performance
• formulation stability shelf-life claims
• patient acceptability (feel, spreading, residue)
• age-based indications (pediatric use)

When the last Orange Book patent for a high-revenue NDC expires, revenue exposure typically shifts quickly because:

• prescribers can switch
• pharmacies can substitute
• payers can reform formularies

Investor-relevant commercial takeaway

In pediculicides, revenue risk is often “cliff-shaped” rather than “gradient,” because patent estates can be thin and entry barriers limited.

---

Which generics and authorized generics typically enter after pediculicide patents expire?

Generic entry scenarios that drive market share

• Immediate post-expiry launch when no additional listed patents remain for the targeted NDC.
• Launch after settlement where originators trade off further litigation risk for a defined earlier or later date.
• Design-around entry where generics avoid specific excipient or concentration claims.

Why NDC-level mapping is critical

A generic can enter for one dosage form or strength while still being blocked for another NDC. In pediculicides, that difference can determine whether a company is fully exposed to competition or only partially.

---

How do pediculicide products compare on IP strategy: permethrin vs ivermectin vs spinosad?

Comparison by typical IP posture

Active ingredient	Typical market role	Usual IP focus	Competitive entry pattern
Permethrin	Often OTC and broadly generic	Older composition histories; later narrow formulation/process if any	Earlier, faster generic saturation
Ivermectin	More likely prescription-led in some segments	Formulation + dosing regimen protection	Entry timing tied to one or two key patents
Spinosad	Prescription-led where used	Composition + stability + dosing regimen	Entry blocked until last listed product patent clears

---

Where are the biggest regulatory and labeling barriers to generic pediculicide entry?

Labeling-driven barriers

Even when generics are AB-rated on active ingredient, product entry can be delayed by:

• differences in recommended retreatment schedules
• instructions that affect how method-of-use claims are implicated
• pediatric and age indication language

Practical outcome

Generic entry barriers are often less about regulatory rejection and more about infringement exposure and settlement dynamics tied to Orange Book listings.

---

Key Takeaways

• Pediculicide patent landscapes are product- and dosage-form specific, with the strongest protection typically in formulation and stability claims rather than broad class-wide coverage.
• Orange Book status generally governs the actual “time-to-launch” more than generic expectations based on active-ingredient aging alone.
• Generic entry risk is timing-driven, with revenue exposure often shifting rapidly after expiration of the last listed NDC-relevant patent.
• Litigation and Paragraph IV challenges function as launch-timing instruments because many pediculicide estates are narrow.
• Biosimilar-style risk is not a central framework for pediculicides; competition is dominated by small-molecule generics and authorized generics plus OTC substitution.

---

FAQs

1. Which Orange Book patents most often block pediculicide generics: formulation patents or method-of-use patents?
2. How do retail OTC substitutes affect the pricing power of prescription pediculicide brands after patent expiry?
3. What design-around strategies are most common for pediculicide formulation patents (vehicle, excipients, concentration ranges)?
4. How do retreatment instructions and pediatric label language influence infringement arguments for method-of-use claims in pediculicides?
5. What settlement structures are most typical in pediculicide Paragraph IV cases, and how do they shape launch dates by NDC?

---

References

1. FDA. “Drugs@FDA: FDA Approved Drug Products.” US Food and Drug Administration.
2. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” US Food and Drug Administration.
3. FDA. “Purple Book: Lists of Licensed Biological Products.” US Food and Drug Administration.